Ph IIA Study (SOC +/- NS5B)
clinical trial
Press Enter · cited answer in seconds
0 sources
Ph IIA Study (SOC +/- NS5B)
Summary
Ph IIA Study (SOC +/- NS5B) is a clinical trial[1].
Key Facts
- Ph IIA Study (SOC +/- NS5B) is in the country of United States[2].
- Ph IIA Study (SOC +/- NS5B)'s instance of is recorded as clinical trial[3].
- Ph IIA Study (SOC +/- NS5B)'s start time is recorded as +2010-10-31T00:00:00Z[4].
- Ph IIA Study (SOC +/- NS5B)'s end time is recorded as +2011-06-30T00:00:00Z[5].
- Ph IIA Study (SOC +/- NS5B)'s sponsor is recorded as Bristol-Myers Squibb[6].
- Ph IIA Study (SOC +/- NS5B)'s main subject is recorded as hepatitis[7].
- Ph IIA Study (SOC +/- NS5B)'s main subject is recorded as hepatitis C[8].
- Ph IIA Study (SOC +/- NS5B)'s number of participants is recorded as {'unit': '1', 'amount': '+39'}[9].
- Ph IIA Study (SOC +/- NS5B)'s title is recorded as A Phase 2A Study of BMS-791325 in Combination With Peg Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve Subjects With Chronic Hepatitis C Virus Genotype 1 Infection[10].
- Ph IIA Study (SOC +/- NS5B)'s short name is recorded as HEPCAT[11].
- Ph IIA Study (SOC +/- NS5B)'s minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[12].
- Ph IIA Study (SOC +/- NS5B)'s ClinicalTrials.gov ID is recorded as NCT01193361[13].
- Ph IIA Study (SOC +/- NS5B)'s maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+70'}[14].
- Ph IIA Study (SOC +/- NS5B)'s research intervention is recorded as interferon-alpha[15].
- Ph IIA Study (SOC +/- NS5B)'s clinical trial phase is recorded as phase II clinical trial[16].
- Ph IIA Study (SOC +/- NS5B)'s research site is recorded as Loyola University Medical Center[17].
- Ph IIA Study (SOC +/- NS5B)'s research site is recorded as Mercy Medical Center[18].
- Ph IIA Study (SOC +/- NS5B)'s study type is recorded as interventional study[19].